Therapeutic Advances in Medical Oncology期刊中文簡介

《腫瘤學治療進展》(TAM)是一份經過同行評審的開放獲取期刊，專注于癌癥醫學治療方面的開拓性努力和創新研究。該雜志是出版倫理委員會(COPE)的成員之一。醫學腫瘤學的治療進展提供了最高質量的同行評審的原始研究文章、評論和學術評論，對癌癥醫學治療的開創性努力和創新性研究。該雜志具有很強的臨床和藥理學焦點，旨在吸引臨床和醫學腫瘤學研究人員的國際觀眾，為該領域的最新研究和觀點的快速傳播提供在線論壇。編輯們歡迎所有腫瘤學領域的原創研究文章。該雜志主要發表原創研究文章和評論文章。原始研究手稿可能包括實驗室、動物或人類/臨床研究——所有階段。給編輯的信和案例報告也將被考慮。審查文章包括專家意見/觀點審查（包括單藥和藥物類審查）、敘述性審查和治療領域審查。系統綜述、薈萃分析、郵戳和健康經濟和藥物經濟評論也受到歡迎。應遵循適當的赤道網絡報告指南（如隨機對照試驗聯合會和系統回顧/薈萃分析Prisma）。該雜志贊同ICMje的要求，即臨床試驗應在首次患者登記時或之前在世衛組織批準的公共試驗登記處登記。但是，與所有試驗活動一致，如果可以接受延遲注冊的理由，將考慮回顧性注冊試驗。該雜志堅持一個盲目的審查過程，在這個過程中，審查者的名字通常不會透露給作者，除非審查者要求公開他們的身份。手稿由至少兩名評審人進行評審；第一次編輯決定通常在提交后3周內作出，在線第一次出版通常在接受后3周內作出。

　　Therapeutic Advances in Medical Oncology期刊英文簡介

Therapeutic Advances in Medical Oncology (TAM) is a peer-reviewed open access journal which focuses on pioneering efforts and innovative studies in the medical treatment of cancer. The journal is a member of the Committee on Publication Ethics (COPE).Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.The editors welcome original research articles across all areas of oncology.The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance.

　　Therapeutic Advances in Medical Oncology期刊近年期刊自引率趨勢圖

　　Therapeutic Advances in Medical Oncology期刊JCR分區

JCR分區等級	JCR所屬學科	分區	影響因子
Q2	ONCOLOGY	Q2	5.485

　　Therapeutic Advances in Medical Oncology近年期刊影響因子趨勢圖

　　Therapeutic Advances in Medical Oncology期刊CiteScore數值

CiteScore	SJR	SNIP	學科類別	分區	排名	百分位
8.50	1.488	1.352	大類：Medicine 小類：Oncology	Q1	57 / 360	84%

　　相關醫學SCI期刊推薦

• BimonthlyJANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE
• MonthlyJOURNAL OF REHABILITATION MEDICINE
• QuarterlyPHARMACOLOGICAL REVIEWS
• QuarterlyJournal of Community Health Nursing
• MonthlyJOURNAL OF CLINICAL MICROBIOLOGY
• WeeklyLANCET
• MonthlyJOURNAL OF MAGNETIC RESONANCE IMAGING
• QuarterlyCANCER AND METASTASIS REVIEWS
• QuarterlyCLINICS IN PLASTIC SURGERY
• MonthlyActas Urologicas Espanolas